Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events
12 mai 2023 11h00 HE
|
Amarin Corporation plc
— New Research Demonstrates Multifactorial Beneficial Effects of VASCEPA/VAZKEPA on Coronary Physiology and Plaque Progression — --Data Further Advances Understanding of VASCEPA/VAZKEPA Potential...
Amarin Reports First Quarter 2023 Financial Results and Provides Business Update
03 mai 2023 07h00 HE
|
Amarin Corporation plc
-- Stable Revenue and Cash Position Due to Performance of U.S. Business and Savings from Operational Initiatives -- -- Early Progress in Launch of VAZKEPA® (icosapent ethyl) in England & Wales;...
Amarin to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023
19 avr. 2023 08h00 HE
|
Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., April 19, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that it will host a conference call with Aaron Berg, Interim President...
Amarin Names Aaron Berg Interim President & Chief Executive Officer and Adds Oliver O’Connor to Company’s Board of Directors
17 avr. 2023 07h00 HE
|
Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER, N.J., April 17, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company’s Board of Directors has appointed Aaron Berg,...
Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved by Israel's Ministry of Health
04 avr. 2023 08h00 HE
|
Amarin Corporation plc
-- Approval of VAZKEPA® to Reduce the Risk of Cardiovascular (CV) Events in Adult Statin-Treated Patients at High CV Risk with Elevated Triglycerides and Other High-Risk Characteristics as Studied in...
Reconstituted Amarin Board Ready for the Challenge of Unlocking True Potential of VASCEPA®/VAZKEPA® (Icosapent Ethyl)
16 mars 2023 08h00 HE
|
Amarin Corporation plc
New Amarin Board Believes the Company Will Thrive with Proper Stewardship New Amarin Directors are Working with Urgency to Address Issues at Amarin DUBLIN, Ireland and BRIDGEWATER, N.J., March 16,...
Amarin Announces Board Departures
06 mars 2023 16h05 HE
|
Amarin Corporation plc
DUBLIN, Ireland and BRIDGEWATER. N.J., March 06, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) (“Amarin” or the “Company”) today announced that, in the interest of the Company to...
Amarin Highlights New Evidence of Therapeutic Value of EPA in Reducing Cardiovascular Events in At-Risk Patients Presented at ACC.23/WCC
06 mars 2023 08h00 HE
|
Amarin Corporation plc
--In Vitro Data Presentations Support Antithrombotic and Antioxidant Effects of EPA Compared with DHA, No Impact of Mineral Oil on Rates of LDL Oxidation -– DUBLIN, Ireland and BRIDGEWATER, N.J.,...
Amarin Announces New REDUCE-IT® Data at ACC.23/WCC Showing Benefit of VASCEPA®/VAZKEPA® (Icosapent Ethyl) in High-Risk Patients with a Recent Acute Coronary Syndrome Event
05 mars 2023 10h21 HE
|
Amarin Corporation plc
--Post-Hoc Analysis Shows IPE Significantly Reduced Risk of First, Total Ischemic Events by 37% and 36% Respectively in Patients with Recent ACS Without Increased Bleeding-- --Analysis Builds on...
Amarin Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
01 mars 2023 07h00 HE
|
Amarin Corporation plc
-- Company Delivers Positive Free Cash Flow in Fourth Quarter 2022 Following U.S. Revenue Stabilization -- -- Previously Announced Cost Savings Program On-Track to Exceed $100 Million Target -- --...